Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Gains from Investment Securities: 2017-2024

Historic Gains from Investment Securities for Crinetics Pharmaceuticals (CRNX) over the last 8 years, with Dec 2024 value amounting to $13.7 million.

  • Crinetics Pharmaceuticals' Gains from Investment Securities rose 70.08% to -$4.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $54.2 million, marking a year-over-year increase of 67.51%. This contributed to the annual value of $13.7 million for FY2024, which is 8.23% up from last year.
  • According to the latest figures from FY2024, Crinetics Pharmaceuticals' Gains from Investment Securities is $13.7 million, which was up 8.23% from $12.6 million recorded in FY2023.
  • Crinetics Pharmaceuticals' 5-year Gains from Investment Securities high stood at $6.6 billion for FY2021, and its period low was $9.8 million during FY2022.
  • For the 3-year period, Crinetics Pharmaceuticals' Gains from Investment Securities averaged around $12.0 million, with its median value being $12.6 million (2023).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first soared by 141,280.88% in 2020, then tumbled by 99.85% in 2022.
  • Yearly analysis of 5 years shows Crinetics Pharmaceuticals' Gains from Investment Securities stood at $4.4 billion in 2020, then skyrocketed by 48.22% to $6.6 billion in 2021, then slumped by 99.85% to $9.8 million in 2022, then grew by 29.41% to $12.6 million in 2023, then grew by 8.23% to $13.7 million in 2024.